T268A Common Cold Spray

In 2015, Karo Pharma acquired a patent-protected common cold product in the late development phase. The cold spray relieves and prevents the progress of the common cold by strengthening the body’s own defenses to fight the cold virus. The patent-protected technique is based on research at the University of Umeå in Sweden and utilizes the enzyme glucose oxidase in combination with glucose to prevent rhinovirus infections and other viral bacterial pathogens. Complementary clinical studies are ongoing.